Asthma treatment in general practice
This review describes the current Danish guidelines for inhaled asthma treatment. Monotherapy with short-acting beta-agonists (SABA) taken when needed is no longer recommended in asthma therapy for adults due to safety concerns. The recommended first-line treatment is now inhaled corticosteroids (ICS) taken with formoterol or ICS taken with SABA. The choice of inhaler can have a significant impact on compliance and symptom control, and an individualized approach is therefore needed. Biological treatment may be an alternative to oral corticosteroids in selected patient groups.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:184 |
|---|---|
| Enthalten in: |
Ugeskrift for laeger - 184(2022), 2 vom: 10. Jan. |
| Sprache: |
Dänisch |
|---|
| Beteiligte Personen: |
Behrendt, Victor [VerfasserIn] |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 24.01.2022 Date Revised 24.01.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM33558344X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33558344X | ||
| 003 | DE-627 | ||
| 005 | 20231225230159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||dan c | ||
| 028 | 5 | 2 | |a pubmed24n1118.xml |
| 035 | |a (DE-627)NLM33558344X | ||
| 035 | |a (NLM)35023469 | ||
| 035 | |a (PII)V03210221 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dan | ||
| 100 | 1 | |a Behrendt, Victor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Asthma treatment in general practice |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2022 | ||
| 500 | |a Date Revised 24.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This review describes the current Danish guidelines for inhaled asthma treatment. Monotherapy with short-acting beta-agonists (SABA) taken when needed is no longer recommended in asthma therapy for adults due to safety concerns. The recommended first-line treatment is now inhaled corticosteroids (ICS) taken with formoterol or ICS taken with SABA. The choice of inhaler can have a significant impact on compliance and symptom control, and an individualized approach is therefore needed. Biological treatment may be an alternative to oral corticosteroids in selected patient groups | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a Ethanolamines |2 NLM | |
| 650 | 7 | |a Formoterol Fumarate |2 NLM | |
| 650 | 7 | |a W34SHF8J2K |2 NLM | |
| 700 | 1 | |a Hilberg, Ole |e verfasserin |4 aut | |
| 700 | 1 | |a Bakker, Vibeke |e verfasserin |4 aut | |
| 700 | 1 | |a Ulrik, Charlotte Suppli |e verfasserin |4 aut | |
| 700 | 1 | |a Bjerring, Niels |e verfasserin |4 aut | |
| 700 | 1 | |a Løkke, Anders |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ugeskrift for laeger |d 1945 |g 184(2022), 2 vom: 10. Jan. |w (DE-627)NLM000011185 |x 1603-6824 |7 nnns |
| 773 | 1 | 8 | |g volume:184 |g year:2022 |g number:2 |g day:10 |g month:01 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 184 |j 2022 |e 2 |b 10 |c 01 | ||